The invention relates to recombinant fusion proteins comprising a fibrinogenolytic enzyme containing an amino acid sequence that is C-terminally and/or N-terminally linked to the amino acid sequence of at least one high-molecular inert stabilization domain having a relative molecular mass >; 50 kDa, for the prevention or treatment of adhesions of tissues or organs, especially peritoneal adhesions following surgeries.